The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Regulatory News

OMB proposal to sideline peer review sparks widespread opposition

Nearly 500,000 public comments flood in—here are some highlights

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The Trump administration’s effort to give political appointees greater authority over federally-funded science is colliding with fierce objections from researchers, universities, medical organizations, and members of Congress. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Table of Contents

YOU MAY BE INTERESTED IN

White House

Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship

Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
By Paul Goldberg
Byline
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account